Êü¼ÍÀþÍøÍѵ»½Ñ¥Ç¡¼¥¿¥Ù¡¼¥¹¤Î¥á¥¤¥ó¥Ú¡¼¥¸¤Ø

ºîÀ®¡§ 2000/1/20 ¾®Åè¡¡Âó¼£

¥Ç¡¼¥¿Èֹ桡¡¡¡¡¡§040180
Í¢·ìÍÑ·ì±Õ¤ÎÊü¼ÍÀþ¾È¼Í½èÍý¤Ë¤ª¤±¤ëÀþÎÌɾ²Á
ÌÜŪ¡¡¡¡¡¡¡¡¡¡¡¡¡§·ì±Õ¾È¼Í½èÍý¤Ë¤ª¤±¤ëÉʼÁ´ÉÍý
Êü¼ÍÀþ¤Î¼ïÊÌ¡¡¡¡¡§¥¨¥Ã¥¯¥¹Àþ,¥¬¥ó¥ÞÀþ,ÅÅ»Ò
Êü¼ÍÀþ¸»¡¡¡¡¡¡¡¡¡§137Cs, 60Co, ¼«¸Ê¼×Ê÷¿XÀþ¸», ¼«¸Ê¼×Ê÷¿ÅÅ»ÒÀþ¾È¼ÍÁõÃÖ
ÀþÎÌ¡ÊΨ¡Ë¡¡¡¡¡¡¡§15-50Gy
ÍøÍÑ»ÜÀß̾¡¡¡¡¡¡¡§Î㤨¤Ð¡¢ÆüËÜÀÖ½½»ú¥»¥ó¥¿¡¼
¾È¼Í¾ò·ï¡¡¡¡¡¡¡¡¡§Â絤Ãæ
±þÍÑʬÌî¡¡¡¡¡¡¡¡¡§Î×¾²°å³Ø¡¢Ìȱֳء¢Í¢·ìµ»½Ñ

³µÍס¡¡¡¡¡¡¡¡¡¡¡¡§
¡¡Í¢·ìÍѤηì±ÕÃæ¤Î¥ê¥ó¥Ñµå¤ÎƯ¤­¤¬¶¯¤¤¤È¡¢¤½¤ì¤òÍ¢·ì¤µ¤ì¤¿´µ¼Ô¤¬»à¤Ë»ê¤ë¤³¤È¤¬¤¢¤ë¡£¤³¤ÎËɻߤËÍ£°ìÍ­¸ú¤ÊÊýË¡¤È¤·¤Æ¡¢Í¢·ìÍÑ·ì±Õ¤ÎÊü¼ÍÀþ¾È¼Í½èÍý¤¬¤¢¤ë¡£¤³¤ÎÊýË¡¤Ç¤Ï¡¢Êü¼ÍÀþ¾È¼ÍÎ̤òÀ©¸æ¤¹¤ë¤³¤È¤Ë¤è¤ê·ì±ÕÃæ¤Î¾¤ÎÀ®Ê¬¤Îµ¡Ç½¤òÍî¤È¤µ¤º¤Ë¥ê¥ó¥Ñµå¤Î³èÀ­¤Î¤ß¤òÄã²¼¤µ¤»¤ë¤³¤È¤¬¤Ç¤­¤ë¡£¤³¤ÎÊü¼ÍÀþ½èÍý¤Ë¤ª¤¤¤Æ¤Ï¡¢ÀþÎ̬Äê¤Ë´ð¤Å¤¯ÉʼÁ´ÉÍý¤¬Æä˽ÅÍפǤ¢¤ë¡£

¾ÜºÙÀâÌÀ¡¡¡¡¡¡¡¡¡§
¡¡Í¢·ìÍÑ·ì±Õ¤ÏÁý¿£²Äǽ¤Ê¥ê¥ó¥Ñµå¤ò´ÞÍ­¤·¤Æ¤ª¤ê¡¢Í¢·ì¤Ë¤è¤ê¡¢¾ì¹ç¤Ë¤è¤Ã¤Æ¤Ï¡¢´µ¼Ô¤ÎÂÎÁÈ¿¥¤ò¹¶·â¡¢½ý³²¤¹¤ë¤³¤È¤¬¤¢¤ë¡£¤³¤ì¤òÍ¢·ì¸åGVHD(Graft versus host disease:°Ü¿¢ÊÒÂнɼçÉÂ)¤È¤¤¤¤¡¢°ìÅÙȯ¾É¤¹¤ë¤ÈÍ­¸ú¤Ê¼£ÎżêÃʤϤʤ¯95%°Ê¾å¤ÏÃ×»àŪ¤Ê·Ð²á¤ò¤¿¤É¤ë¡£¤³¤Î¤¿¤á¡¢Æñ¤·¤¤¼ê½Ñ¤¬À®¸ù¤·¤Æ¤â̵°Ù¤Ëµ¢¤·¤Æ¤·¤Þ¤¦¤³¤È¤Ë¤Ê¤ë¡£1985ǯ¤ÎÄ´ºº¤Ë¤è¤ì¤Ð³«¿´¼ê½Ñ¾ÉÎã¤Ç659·ï¤Ë1·ï¤Î³ä¹ç¤Çȯ¸½¤·¤Æ¤ª¤ê¡¢¤Þ¤¿¡¢1993ǯ¤«¤é¤Î3ǯ´Ö¤ÇÍ¢·ìÍÑ·ì±Õ¤Ë¤è¤ëGVHDȯ¸½¤¬29Îã¤âÊó¹ð¤µ¤ì¤Æ¤¤¤ë¡£¤³¤Î¼À´µÈ¯¾É³ÎΨ¤Ï¡¢Åç¹ñ¤Ç°äÅÁŪÊа̤ξ¯¤Ê¤«¤Ã¤¿ÆüËܿͤËÆäË¿¤¯ÊƹñÇò¿Í¤ÎÌó8ÇܤǤ¢¤ë¡£
¡¡¤³¤Î¼À´µ¤Ë¤Ä¤¤¤Æ¤Ï̤¤À²Ê³ØŪ¤ÊÉ°ø¤Î²òÌÀ¤¬¤Ê¤µ¤ì¤Æ¤¤¤Ê¤¤¤¿¤á¡¢È¯¾É¤¹¤ë¤ÈÍ­¸ú¤Ê¼£ÎżêÃʤ¬¤Ê¤¯¡¢Í¢·ì±ÕÃæ¤Î¥ê¥ó¥Ñµå¤Î½üµî¤Þ¤¿¤Ï¼º³è¤Ë¤è¤ëͽËɺö¤¬ºÎ¤é¤ì¤Æ¤¤¤ë¡£¤³¤ì¤Þ¤Ç¤Ï±ó¿´Ê¬Î¥¤ä¥Õ¥£¥ë¥¿¡¼ÍøÍѤˤè¤ë½üµî¤¬¹Ô¤ï¤ì¤Æ¤¤¤¿¤¬¡¢¸úΨ¤ä³Î¼ÂÀ­¤ÎÅÀ¤ÇÉÔ½½Ê¬¤Ç¤¢¤Ã¤¿¡£¤³¤ì¤ËÂФ·¡¢¥ê¥ó¥Ñµå¤ò´Þ¤àÁ´¤Æ¤ÎÍ¢·ìÍÑ·ì±Õ¤ËÊü¼ÍÀþ¤ò¾È¼Í¤¹¤ë¤È¡¢¥ê¥ó¥Ñµå¤ÎÊü¼ÍÀþ´¶¼õÀ­¤¬ÀÖ·ìµå¤ä·ì¾®ÈÄÅù¤è¤ê¤â¤ä¤ä¹â¤¤¤¿¤á¡¢¾È¼ÍÎ̤ÎÀ©¸æ¤Ë¤è¤ê¾¤ÎÀ®Ê¬¤Îµ¡Ç½¤òÍî¤È¤¹¤³¤È¤Ê¤¯¥ê¥ó¥Ñµå¤Î¤ß¤ò¼º³è¤µ¤»¤ë¤³¤È¤¬¤Ç¤­¤ë¡£¤³¤Î¤è¤¦¤Ê·Ð°Þ¤«¤é¡¢¸½ºß¤Ç¤Ï·ì±Õ¤ÎÊü¼ÍÀþ¾È¼Í¤¬ÉáµÚ³ÈÂ礷¤Ä¤Ä¤¢¤ë¡£
¡¡¾È¼Í¤·¤¿·ì±Õ¤ÎÉʼÁ´ÉÍý¤Ï´µ¼Ô¤ÎÀ¸Ì¿¤Ë·¸¤ï¤ë¤¿¤áÈó¾ï¤Ë½ÅÍפǤ¢¤ê¡¢Êü¼ÍÀþ¾È¼Í¤Ë´Ø¤¹¤ë¥¬¥¤¥É¥é¥¤¥ó¤¬¹ñºÝŪ¤Ë¤âºöÄꤵ¤ì¤Ä¤Ä¤¢¤ë¡£¹ñÆâ¤Ç¤Ï1992ǯ¤è¤êÆüËÜÍ¢·ì³Ø²ñ¤¬ºöÄê¤ò¿Ê¤á¤Æ¤ª¤ê¡¢1999ǯ¤Ë¡ÖÍ¢·ì¤Ë¤è¤ëGVHDͽËɤΤ¿¤á¤Î·ì±Õ¤ËÂФ¹¤ëÊü¼ÍÀþ¾È¼Í¥¬¥¤¥É¥é¥¤¥óIV¡×¤¬½Ð¤µ¤ì¤Æ¤¤¤ë¡£
¡¡°ìÈÌŪ¤Ë¡¢·ì±Õ¾È¼Í¤Ë»ÈÍѤµ¤ì¤ëÀþ¸»¤ÏXÀþ¸»¤È¥¬¥ó¥ÞÀþ¸»¤Ç¤¢¤ë¡£Á°¼Ô¤Ë¤Ä¤¤¤Æ¤Ï¡¢XÀþ´Éµå¤ÎÅÅ°µ¤¬150µÚ¤Ó210kV¤ÎXÀþȯÀ¸ÁõÃÖ¡¢¸å¼Ô¤Ë¤Ä¤¤¤Æ¤Ï¼ç¤È¤·¤Æ137Cs(Ⱦ¸º´ü30.07ǯ¡¢662keV)µÚ¤Ó60Co(Ⱦ¸º´ü5.27ǯ¡¢1.17MeV¤È1.33MeV)¤ò¼«¸Ê¼×Ê÷¿¥»¥ë¤Ë¼ýǼ¤·¤¿¤â¤Î¤Þ¤¿¤ÏÊü¼ÍÀþ¼£ÎÅÍÑ¥Ó¡¼¥à¾õ¾È¼ÍÁõÃÖ¤¬¤¢¤ë¡£¿Þ1¤Ë¼«¸Ê¼×Ê÷¿¥»¥ë¤ÎÎã¤ò¼¨¤¹¡£·ì±Õ¥Ð¥Ã¥°¤Ï¡¢¥»¥ë³°Éô¤Ë¤¢¤ëÅêÆþ¸ý¤ËÃÖ¤­¡¢¤³¤ÎÉôʬ¤¬²óž¤¹¤ë¤³¤È¤Ë¤è¤êÁõÃÖÆâÉô¤Î¾È¼ÍÌî¤ËƳÆþ¤µ¤ì¾È¼Í¤µ¤ì¤ë¡£¼ýǼÊü¼Íǽ¤Ï200TBq(5,405Ci)¤¬¾å¸Â¤Ç¡¢¾È¼Í½êÍ×»þ´Ö¤Ï¿ôʬ¤«¤é¿ô10ʬ¤Ç¤¢¤ë¡£
¡¡Êü¼ÍÀþ¾È¼ÍÀþÎ̤ϡ¢Í¢·ì¸åGVHD¤Î¸¶°ø¤È¤µ¤ì¤Æ¤¤¤ëT-¥ê¥ó¥Ñµå¤ÎÁý¿£¤òÍÞÀ©¤¹¤ë¤¿¤á¤ËɬÍפÊ15Gy¤ò²¼¸Â¤È¤·¡¢ÀÖ·ìµå¡¢·ì¾®ÈÄ¡¢ðùγµå¤Îµ¡Ç½¤ä¼÷Ì¿¤ò»¤Ê¤ï¤Ê¤¤50Gy¤ò¾å¸Â¤È¤·¤Æ¤¤¤ë¡£¤³¤ÎÀþÎÌÈÏ°Ï·èÄê¤Îº¬µò¤È¤Ê¤ë·ì±ÕºÙ˦¤ËµÚ¤Ü¤¹Êü¼ÍÀþ¾È¼Í¤Î±Æ¶Á¤òɽ1¤Ë¼¨¤¹¡£

ɽ1¡¡·ì±ÕºÙ˦¤ËµÚ¤Ü¤¹Êü¼ÍÀþ¾È¼Í¤Î±Æ¶Á.¡Ê¸¶ÏÀʸ4¤è¤ê°úÍÑ¡£¡¡­ê¥á¥Ç¥£¥«¥ë¥á¥µ¥¤¥¨¥ó¥¹¡¦¥¤¥ó¥¿¡¼¥Ê¥·¥ç¥Ê¥ë¤Î¤´¾µÇ§¤Ë´ð¤Å¤­¡¢Èæα´Ö·é¡¢Àõ°æδÁ±¡¢À±½çδ¡¡¶¦Ãø¡§¡Ö°ìÌܤǤ狼¤ëÍ¢·ì¡×(³ô¼°²ñ¼Ò¥á¥Ç¥£¥«¥ë¡¦¥µ¥¤¥¨¥ó¥¹¡¦¥¤¥ó¥¿¡¼¥Ê¥·¥ç¥Ê¥ë, 1998) p.72-75¡¢É½36-1 (Data source 4, pp.74)¤«¤éžºÜ¤·¤¿¤â¤Î¤Ç¤¹¡Ë
----------------------------------------------------------------------------------------
 ·ì±ÕºÙ˦                               ¾È¼ÍÀþÎÌ¡ÊGy)
            ----------------------------------------------------------------------------
             10          15          30          50          50¡Á100         <100
----------------------------------------------------------------------------------------
  ÀÖ·ìµå                 K+Ç»ÅÙÁý²Ã              Ⱦ¼÷Ì¿30%Äã²¼               pH,ATPÀµ¾ï
                                                 Í·Î¥HbÉÔÊÑ                  Í·Î¥HbÀµ¾ï
----------------------------------------------------------------------------------------
  ·ì¾®ÈÄ                                         Ⱦ¼÷Ì¿ÉÔÊÑ  ¶Å½¸Ç½ÉÔÊÑ
----------------------------------------------------------------------------------------
         PHA 20¡Á30%¤ËÄã²¼           10¡Á15%¤ËÄã²¼           0¡Á5%¤ËÄã²¼
¥ê¥ó¥Ñµå -------------------------------------------------------------------------------
         MLC             10%°Ê²¼¤ËÄã²¼                       ¾Ã¼º
         -------------------------------------------------------------------------------
ðùγµå                                           Áö²½Ç½ÉÔÊÑ  ìÅ¿©Ç½20%Äã²¼
                                                             »ÀÁǾÃÈñÎÌ30%Äã²¼
----------------------------------------------------------------------------------------
¡¡·ì±Õ¤Î¾È¼Í¤Ë¤ª¤±¤ëÉʼÁ´ÉÍý¤ÏÀþÎ̬Äê¤Ë´ð¤Å¤¤¤Æ¹Ô¤¦É¬Íפ¬¤¢¤ë¡£¤·¤¿¤¬¤Ã¤Æ¡¢¾È¼Í·ì±Õ¤Î¤¤¤º¤ì¤ÎÉôʬ¤â¾åµ­¤ÎÀþÎÌÈÏ°ÏÆâ¤Ë¤Ê¤ë¤è¤¦¤Ë¡¢²¼µ­¤Î¼ê½ç¤¬½ÅÍפǤ¢¤ë¡£¤Ê¤ª¡¢Á°½Ò¤Î¥¬¥¤¥É¥é¥¤¥ó¤ÎÉÕ°¡Ö·ì±Õ¾È¼ÍÁõÃÖ´ÉÍý¥Þ¥Ë¥å¥¢¥ë¡×¤Ë¤â¤³¤ì¤é¤Ë´Ø¤¹¤ëƱÍͤε­½Ò¤¬¤¢¤ë¡£
¡¡1)¾È¼ÍÌî¤Î¸ÇÄê°ÌÃ֤ˤª¤±¤ëÀþÎ̬Äê¤Ë´ð¤Å¤¯½ÐÎÏÆÃÀ­¤Î³Îǧ
¡¡2)¾È¼ÍÁõÃÖÆâ¶õ´Ö¤ÎÀþÎÌΨʬÉÛµÚ¤Ó¥Õ¥¡¥ó¥È¥à(¥¢¥¯¥ê¥ëÈĤޤ¿¤ÏÇÑ´þ·ì±Õ¥Ð¥Ã¥¯Åù)¤ò½¼Å¶¤·¤¿¾õÂ֤ˤª¤±¤ëÀþÎÌΨʬÉÛ(¶Ñ°ìÀ­)¤Î¥Ð¥ê¥Ç¡¼¥·¥ç¥ó
¡¡3)¾åµ­¤Î¥Ç¡¼¥¿¤Ë´ð¤Å¤­Äê¤á¤¿¤¢¤ëÆÃÄê°ÌÃ֤ˤª¤±¤ëÀþÎ̬Äê·ë²Ì¤Ë¤è¤ë´ð½àÀþÎ̾ȼÍãÀ®¤Î³Îǧ
¡¡ÀþÎ̷פˤϡ¢Í½¤á¹ñ²Èɸ½àÅù¤Ç60Co¦ÃÀþ¤ËÂФ·¤Æ¹»Àµ¤·¤¿¤â¤Î¤ò»ÈÍѤ¹¤ë¡£ÀþÎ̵ڤÓÀþÎÌʬÉÛ¬Äê¤Ë¤ª¤¤¤Æ¡¢½½Ê¬¤Ê¶õ´Ö¤¬¤¢¤ë¾ì¹ç¤ÏÅÅΥȢ¤òÍѤ¤¡¢¶¹¤¤¶õ´Ö¤Î¾ì¹ç¤Ç¤ÏÇ®¥ë¥ß¥Í¥»¥ó¥¹(TLD)ÀþÎ̷פ䥢¥é¥Ë¥óÀþÎÌ·×Åù¤òÍѤ¤¤ë¡£ÁƤ¤ÀþÎÌΨʬÉÛ¬Äê¤Ë¤ÏXÀþ¥Õ¥£¥ë¥àÅù¤òÍѤ¤¤ë¾ì¹ç¤â¤¢¤ë¡£ÀþÎ̬Äê¾å¤ÎÃí°ÕÅÀ¤È¤·¤Æ¤Ï¡¢Æó¼¡ÅÅ»ÒÊ¿¹Õ¾ò·ï¤¬À®¤êΩ¤Ä¤³¤È¡¢»¶ÍðÀþ¤Î±Æ¶Á(10%ÄøÅÙ)¤ò¹Íθ¤¹¤ë¤³¤È¡¢µÚ¤ÓXÀþ¾È¼Í¤Ç¤ÏXÀþ´Éµå¤«¤é¤ÎÊüÇ®Åù¤Ë¤è¤ë²¹Åپ徺¤ËÃí°Õ¤¹¤ë¤³¤È¤¬¤¢¤²¤é¤ì¤ë¡£Àµ³Î¤Ç¤Ï¤Ê¤¤¤¬¡¢¡Ö¾È¼ÍºÑ¤ß¡×³Îǧ¤¢¤ë¤¤¤Ï̤¾È¼Í¡¦¾È¼Í¤Î¶èÊ̤Τ¿¤á¤Ë¡¢¿§ÊѲ½¤òÍøÍѤ·¤¿¥Þ¡¼¥«¡¼¤â»ÈÍѤµ¤ì¤ë¡£°ìÊý¡¢¾È¼ÍÂоݤȤʤë·ì±Õ¤Î´ÑÅÀ¤«¤é¤Ï¡¢¶Ñ°ì¤ÊÀþÎ̤ò¾È¼Í¤Ç¤­¤ë¤è¤¦¤Ëȿž¡¦¿¶Æ°¡¦³ÉÙÂÅù¤ÎɬÍ×À­¤Î¸¡Æ¤µÚ¤Ó¾È¼Í¤Ë¤è¤ë²¹Åپ徺ËɻߤιÍθ¤¬É¬ÍפǤ¢¤ë¡£Á°¼Ô¤Ë¤Ä¤¤¤Æ¤Ï¡¢Î㤨¤Ð¿Þ1¤Ë¤ª¤¤¤Æ·ì±Õ¥Ð¥Ã¥°¼ýǼÉôʬ¤¬¾È¼ÍÌîÆâ¤Ç¼«Å¾¤ò¤¹¤ë¤Ê¤É¤Ç¤¢¤ë¡£


¿Þ1¡¡·ì±ÕÊü¼ÍÀþ¾È¼ÍÁõÃÖ¤ÎÎã(Ê¿ÌÌÆ©»ë¿Þ).¡Ê¸¶ÏÀʸ4¤è¤ê°úÍÑ¡£¡¡­ê¥á¥Ç¥£¥«¥ë¥á¥µ¥¤¥¨¥ó¥¹¡¦¥¤¥ó¥¿¡¼¥Ê¥·¥ç¥Ê¥ë¤Î¤´¾µÇ§¤Ë´ð¤Å¤­¡¢Èæα´Ö·é¡¢Àõ°æδÁ±¡¢À±½çδ¡¡¶¦Ãø¡§¡Ö°ìÌܤǤ狼¤ëÍ¢·ì¡×(³ô¼°²ñ¼Ò¥á¥Ç¥£¥«¥ë¡¦¥µ¥¤¥¨¥ó¥¹¡¦¥¤¥ó¥¿¡¼¥Ê¥·¥ç¥Ê¥ë,1998) pp.72-75¡¢¿Þ36-1Data source 4, pp.74)¤«¤éžºÜ¤·¤¿¤â¤Î¤Ç¤¹¡£¡Ë

¡¡Êü¼ÍÀþ¾È¼Í¸å¤Ï®¤ä¤«¤ËÍ¢·ì¤Ë»ÈÍѤµ¤ì¤ë¤³¤È¤¬É¬ÍפǤ¢¤ë¡£¤·¤«¤·¡¢Í¢·ìÍÑÁ´·ì¡¢ÀÖ·ìµå¤Ç¤Ï¡¢¿Þ2¤Ë¼¨¤¹¤è¤¦¤Ë¡¢·ìÀ¶Ãæ¤Î¥«¥ê¥¦¥àÃͤ¬ºÎ·ì¸å¾å¾º¤¹¤ë¡£¤½¤·¤Æ¡¢¥«¥ê¥¦¥àÃͤ¬7mEq(Eq:»ÀÁǤò´ð½à¤È¤·¤¿²½³ØÅöÎÌ)°Ê¾å¤Î·ì±Õ¤ò¹â®͢·ì¤¹¤ë¤È¹â¥«¥ê¥¦¥à·ì¾É¤Ë¤è¤ë¿´Ää»ß¤Î¤ª¤½¤ì¤¬¤¢¤ë¤³¤È¤«¤é¡¢¾È¼Í·ì±Õ¤Î´ü¸Â¤ÏºÎ·ì¸å21Æü¤È¤µ¤ì¤Æ¤¤¤ë¡£¤³¤Î¤¿¤á¡¢Ì¤»ÈÍÑ·ì±Õ»Ä±Õ¤ò¾¤Î´µ¼Ô¤ËžÍѤ¹¤ë¤³¤È¤¬¤Ç¤­¤Ê¤¤¾ì¹ç¤ÏÇË´þ¤»¤¶¤ë¤òÆÀ¤º¡¢Í¢·ìÍÑ·ì±Õ¤ÎÍ­¸úÍøÍѤξ㳲¤È¤Ê¤Ã¤Æ¤¤¤ë¡£


¿Þ2¡¡400mlͳÍèÀÖ·ìµåM¡¦A¡¦PÃæ¤Î¾åÀ¶¥«¥ê¥¦¥à(K)ÃÍ.¡Ê¸¶ÏÀʸ3¤è¤ê°úÍÑ¡£¡¡ÆüËÜÍ¢·ì³Ø²ñ¤Î¤´¾µÇ§¤Ë´ð¤Å¤­¡¢Japanese J. Tranfusion Medicine, Vol.45, No.1, 47-54 (1999), ¿Þ£± (Data source 3, pp.52)¤«¤éžºÜ¤·¤¿¤â¤Î¤Ç¤¹¡£¡Ë

¡¡Í¢·ìÍÑ·ì±Õ¤ËÂФ¹¤ëÊü¼ÍÀþ¾È¼Í¤Î°ÂÁ´À­¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤Þ¤À¥Ç¡¼¥¿¤¬ÉÔ­¤·¤Æ¤¤¤ë¤¬¡¢²¼µ­¤Î¤³¤È¤Ëα°Õ¤¹¤ëɬÍפ¬¤¢¤ë¡£
¡¡1)»ÈÍѤ¹¤ëÊü¼ÍÀþ¤Î¥¨¥Í¥ë¥®¡¼¤Ï10MeV̤Ëþ¤È¤··ì±ÕÀ®Ê¬¤ä¾È¼Í¥Ð¥Ã¥°¤¬Êü¼Í²½¤·¤Ê¤¤¾ò·ï¤Î¤â¤Î¤ò»ÈÍѤ¹¤ë¡£
¡¡2)´ð½à¤ÎÀþÎÌÈϰϤǤϼ«¸ÊÊ£À½Ç½¤òÍ­¤¹¤ë¥ê¥ó¥Ñµå¤ä¤·ì´´ºÙ˦¤ËÂФ¹¤ëÊü¼ÍÀþ¤Ë¤è¤ëȯ¥¬¥óͶȯ¥ê¥¹¥¯¤òDNAÊÑ°ÛΨ¤ä¥ê¥ó¥Ñµå¤Î¿¶¤ëÉñ¤¤¤Î³ÎΨ¤«¤é·×»»¤Çµá¤á¤ë¤È¶Ë¤á¤ÆÄ㤤¤¬¡¢º£¸å¥Ò¥È¤Ë´Ø¤¹¤ë°ÂÁ´À­¥Ç¡¼¥¿¤òºÎ¤ëɬÍפ¬¤¢¤ë¡£
¡¡3)Êü¼ÍÀþ¾È¼Í¸å¤ÎÀÖ·ìµå¡¢·ìÞùÈÄÅù¤Îµ¡Ç½¡¢¥«¥ê¥¦¥àÃͤËÂФ¹¤ëÊü¼ÍÀþ¾È¼Í±Æ¶Á¤Ë¤Ä¤¤¤Æ¤â½½Ê¬¤Ê¥Ç¡¼¥¿¤òÃßÀѤ¹¤ëɬÍפ¬¤¢¤ë¡£

¥³¥á¥ó¥È¡¡¡¡¡¡¡¡¡§
¡¡Êü¼ÍÀþÍøÍѤǤϿ·¤·¤¤Ê¬Ìî¤Ç¤¢¤ê¡¢¤Þ¤¿¡¢É°ø²òÌÀ¤äÊü¼ÍÀþ¾È¼Í¸ú²Ì¤Î°ÂÁ´À­Åù¤Î°å³Ø¡¦Î×¾²Åª¤Ê¥Ç¡¼¥¿¤Ë¥Ë¡¼¥º¤¬Àè¹Ô¤·¤Æ¤¤¤ë¤¿¤á¡¢¤Þ¤À¤Þ¤À̤²ò·è¤Ê²ÝÂ꤬»³ÀѤ·¤Æ¤¤¤ë¡£°å³ØŪ¤ÊÌäÂê¤ÏÊ̤ˤ·¤Æ¡¢Êü¼ÍÀþ¾È¼Í¤Ë´Ø¤¹¤ë²ÝÂê¤È¤·¤Æ¡¢°å³ØÍøÍѰʳ°¤ÎÊü¼ÍÀþ¾È¼ÍÍøÍÑʬÌî¤È¤ÎÀÜÅÀ¤¬½½Ê¬¤Ç¤Ê¤¯¡¢Ëɸî¥ì¥Ù¥ë¤ä¼£ÎÅ¥ì¥Ù¥ë¤è¤ê¤â¹â¤¤ÀþÎ̤άÄêµ»½Ñ¤Ë´Ø¤·¤Æ¤âÌ©¤Ê¾ðÊó¸ò´¹¤¬É¬ÍפǤ¢¤ë¡£¤Þ¤¿¡¢¾È¼ÍÁõÃÖ¤¬¹â²Á¤Ç¤¢¤ê¶ÛµÞÀ­¤ËÂбþ¤Ç¤­¤ëÀìÍѾȼÍÁõÃ֤ξȼ͵»½ÑŪ¤ÊÀ߷ס¦À½Â¤¡¢¾È¼Í·ì±Õ¤ÎÉʼÁ´ÉÍý¤Î¤¿¤á¤ÎÀþÎ̬Äê¤Ë´Ø¤¹¤ë¥È¥ì¡¼¥µ¥Ó¥ê¥Æ¥£¤ÎÀ°È÷¤È¬Äê¼ê½ç¤Îɸ½à²½¤Ê¤É¤¬²ÝÂê¤È¹Í¤¨¤ë¡£

¸¶ÏÀʸ£± Data source 1¡§
Pretransfusion blood irradiation:¡¡Clinical rationale and dosimetric consideration
M.E.Masterson and R.Febo
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021 USA
Med. Phys., vol.19(3), May/Jun, p. 649-657 (1992)

¸¶ÏÀʸ£² Data source 2¡§
·ì±Õ¾È¼Í¤«¤é¤ß¤¿Í¢·ì¸åGVHD¤Î¸½¾õ¤È²ÝÂê
´Øº¬¡¡¹­
Åìµþ»ü·Ã²ñ°å²ÊÂç³ØÊü¼ÍÀþ°å³Ø¹ÖºÂ¡¢ÅìµþÅÔ¹Á¶èÀ¾¿·¶¶3-25-8¡¡¡¡
¡Ö¿·°åÎÅ¡×, 1996ǯ 12·î¹æ¡¡p. 128-131 (1996)

¸¶ÏÀʸ£³ Data source 3¡§
ÆüËÜÍ¢·ì³Ø²ñ¡ÖÍ¢·ì¸åGVHDÂкö¾®°Ñ°÷²ñ¡×Êó¹ð
ÆüËÜÍ¢·ì³Ø²ñÍ¢·ì¸åGVHDÂкö¾®°Ñ°÷²ñ(Àõ°æ¡¡Î´Á±¡¢°ðÍÕ¡¡ðó°ì¡¢Âç¸Í¡¡ÀÆ¡¢Ä¹ÅÄ¡¡¹­»Ê¡¢ÎëÌÚ¡¡¸µ¡¢¹â¶¶¡¡¹§´î¡¢ÅĽꡡ·û¼£¡¢ÆΦɧ)
ÆüËÜÀÖ½½»ú¼Ò
Japanese Journal of Tranfusion Medicine, Vol. 45, No. 1, 47-54 (1999)

¸¶ÏÀʸ£´ Data source 4¡§
35Í¢·ì´ØÏ¢°Ü¿¢ÊÒÂнɼçÉÂ(TA-GVHD); 36Í¢·ìÍÑ·ì±Õ¤ÎÊü¼ÍÀþ¾È¼Í
Èæα´Ö¡¡·é
Èæα´Ö¡¡·é¡¢Àõ°æ¡¡Î´Á±¡¢À±¡¡½çδ¡¡¶¦Ãø¡§¡Ö°ìÌܤǤ狼¤ëÍ¢·ì¡×(³ô¼°²ñ¼Ò¥á¥Ç¥£¥«¥ë¡¦¥µ¥¤¥¨¥ó¥¹¡¦¥¤¥ó¥¿¡¼¥Ê¥·¥ç¥Ê¥ë, 1998) p. 72-75

»²¹Í»ñÎÁ£± Reference 1¡§
Standard practice for blood irradiation dosimetry
ASTM Standard E1939-98
American Standards for Testing and Materials
1999 Annual book of ASTM standards, section 12, Vol. 12.02, p. 1001-1011 (1999)

¥­¡¼¥ï¡¼¥É¡§·ì±Õ¾È¼Í, ÀþÎ̬Äê, ÉʼÁÊݾÚ
blood irradiation, dosimetry, quality assurance
ʬÎॳ¡¼¥É¡§010402, 030701, 040302

Êü¼ÍÀþÍøÍѵ»½Ñ¥Ç¡¼¥¿¥Ù¡¼¥¹¤Î¥á¥¤¥ó¥Ú¡¼¥¸¤Ø